ScienceBreaking NewsBreakingLatest News
Ozempic and Wegovy Linked to Rare Risk of Sudden Vision Loss
Sentiment: NeutralHigh Priority
What Happened?
A study by Rutgers researchers indicates that diabetes and weight loss medications, including Ozempic and Wegovy, may increase the risk of ischemic optic neuropathy, a rare condition that can cause sudden vision loss.
Key points
- The study analyzed data from US adults aged 18 to 65 with Type 2 diabetes.
- Ischemic optic neuropathy can lead to sudden and potentially permanent vision loss.
- The risk associated with GLP-1 medications is approximately three to four additional cases per 10,000 patients over 18 months.
- Men and older adults (ages 50 to 65) are more likely to develop this eye condition.
- More than 80% of cases involve the non-arteritic anterior form of ischemic optic neuropathy.
- The findings do not confirm that GLP-1 medications directly cause optic nerve damage.
Key insights
- Patients using GLP-1 medications should be monitored for sudden vision changes.
- Early recognition of symptoms may help prevent permanent vision loss.
- The study underscores the importance of ongoing safety evaluations as GLP-1 medications gain popularity.
Why it matters
The findings highlight the need for awareness of potential vision risks associated with popular diabetes and weight loss medications.
Tags
Entities
Ozempic· ProductWegovy· ProductRutgers University· OrganizationType 2 diabetes· Condition
Source
Science Daily
